Patient characteristics based on response to therapy
Characteristic . | Responders . | Nonresponders . | P . |
|---|---|---|---|
| No. of patients (%) | 12 (23) | 41 (77) | |
| Median age, y (range) | 68 (13-80) | 55 (5-79) | .006 |
| Diagnosis, no. (%) | |||
| Untreated AML | 5 (42) | 4 (10) | .01 |
| Previously treated AML | 4 (34) | 34 (83) | |
| Untreated MDS | 2 (17) | 1 (2) | |
| Previously treated MDS | 1 (8) | 2 (4) | |
| Cytogenetics, no. (%) | |||
| Diploid | 4 (33) | 20 (49) | |
| Inv(16)/t(8;21) | 1 (8) | 1 (2) | |
| Other | 7 (58) | 20 (49) | |
| Prior therapy with DNMT inhibitor, no. (%) | 0 (0) | 1 (2) | |
| Median WBC count, × 109/L (range) | 3.6 (1.3-56.4) | 3.9 (0.6-74.1) | |
| Median platelet count, × 109/L (range) | 41 (20-470) | 26 (4-225) | |
| Median creatinine, mM (range) | 88.4 (70.72-150.28) | 79.56 (17.68-167.96) | |
| Median total bilirubin, mM (range) | 10.26 (3.42-32.49) | 8.55 (3.42-30.78) |
Characteristic . | Responders . | Nonresponders . | P . |
|---|---|---|---|
| No. of patients (%) | 12 (23) | 41 (77) | |
| Median age, y (range) | 68 (13-80) | 55 (5-79) | .006 |
| Diagnosis, no. (%) | |||
| Untreated AML | 5 (42) | 4 (10) | .01 |
| Previously treated AML | 4 (34) | 34 (83) | |
| Untreated MDS | 2 (17) | 1 (2) | |
| Previously treated MDS | 1 (8) | 2 (4) | |
| Cytogenetics, no. (%) | |||
| Diploid | 4 (33) | 20 (49) | |
| Inv(16)/t(8;21) | 1 (8) | 1 (2) | |
| Other | 7 (58) | 20 (49) | |
| Prior therapy with DNMT inhibitor, no. (%) | 0 (0) | 1 (2) | |
| Median WBC count, × 109/L (range) | 3.6 (1.3-56.4) | 3.9 (0.6-74.1) | |
| Median platelet count, × 109/L (range) | 41 (20-470) | 26 (4-225) | |
| Median creatinine, mM (range) | 88.4 (70.72-150.28) | 79.56 (17.68-167.96) | |
| Median total bilirubin, mM (range) | 10.26 (3.42-32.49) | 8.55 (3.42-30.78) |
DNMT inhibitor indicates DNA methyltransferase inhibitor (ie, 5-azacitidine or 5-aza-2′-deoxycitidine); WBC, white blood cell.